Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
 and Lead Plaintiff Deadline - May 28, 2018 - EconoTimes)
NEW YORK, May 02, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sldb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Solid’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) The company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sldb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Solid you have until May 28, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
